Boston OAIC: A Translational Approach to Function Promoting Therapies

波士顿 OAIC:功能促进疗法的转化方法

基本信息

  • 批准号:
    10752906
  • 负责人:
  • 金额:
    $ 39.37万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-09-01 至 2026-06-30
  • 项目状态:
    未结题

项目摘要

Summary The overall objective of this administrative supplement is to support a developmental project linked to the Translational Discovery Core of the Boston Older Americans Independence Center. The primary aim of the project is to optimize liquid chromatography tandem mass spectrometry (LC-MS/MS) assays for the measurement of biologically active mature forms of GDF11, myostatin, oxytocin, and acyl ghrelin that do not have any interference from respective proproteins or related peptides, and that are calibrated against well- characterized standards generated by the CDC's Hormone Standardization Program. The CDC laboratory will generate high quality reference materials to establish the traceability of procedure to a value that represents the best estimate of the true value. The generation of a commutable reference material by the CDC Laboratory will ensure accuracy, and help reduce inter-assay and inter-laboratory variability. Upon successful completion of this developmental project, these harmonized assays will be made available to the investigators within the Boston OAIC and other OAICs, as well as to the scientific community at large through the Translational Discovery Core of the Boston OAIC. These assays will be of substantial value to NIA- funded investigators within Boston OAIC (Bhasin, Wagers, Lee), other OAICs (Lee at University of Connecticut OAIC, Farmington, CT; investigators associated with the CARGO Project) and investigators outside the Pepper Center Network (Lawson at Mass General Hospital; Orwoll at the University of Oregon, Cawthon at UCSF). The availability of accurate and sensitive assays would be a useful resource to many researchers and would extend the range and quality of this NIH-funded research. The project represents a historical opportunity and an important step towards harmonization of optimized assays for the measurement of geronic factors and their related proteins and peptides.
总结 这份行政补充文件的总体目标是支持一个与 波士顿老年美国人独立中心(Boston Older Americans Independence Center)的主要目的 该项目是优化液相色谱串联质谱(LC-MS/MS)分析, 测量GDF 11、肌肉生长抑制素、催产素和酰基生长素释放肽的生物活性成熟形式, 具有来自相应前蛋白或相关肽的任何干扰,并且针对良好的 由CDC的激素标准化计划产生的特征标准。CDC实验室将 生成高质量的参考材料,以建立程序的可追溯性, 真实价值的最佳估计。CDC实验室生成可交换的参考物质 将确保准确性,并有助于减少试验间和实验室间的变异性。 在成功完成该开发项目后,这些协调的检测试剂盒将提供给 波士顿OAIC和其他OAIC的调查人员以及整个科学界 通过波士顿OAIC的翻译发现核心。这些分析将对NIA具有重大价值- 波士顿OAIC(Bhasin,Wagers,Lee),其他OAIC(康涅狄格大学的Lee) OAIC,法明顿,CT;与CARGO项目相关的调查人员)和Pepper以外的调查人员 中心网络(马萨诸塞州总医院的劳森;俄勒冈州大学的奥沃尔,加州大学旧金山分校的考顿)。 准确和灵敏的测定的可用性将是许多研究人员的有用资源, 扩大NIH资助研究的范围和质量。该项目代表了一个历史机遇, 一个重要的步骤,协调优化测定老年因素及其 相关蛋白质和肽。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SHALENDER BHASIN其他文献

SHALENDER BHASIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SHALENDER BHASIN', 18)}}的其他基金

NAD Augmentation to Treat Diabetic Kidney Disease: A Randomized Controlled Trial
NAD 增强治疗糖尿病肾病:一项随机对照试验
  • 批准号:
    10430705
  • 财政年份:
    2022
  • 资助金额:
    $ 39.37万
  • 项目类别:
NAD Augmentation to Treat Diabetic Kidney Disease: A Randomized Controlled Trial
NAD 增强治疗糖尿病肾病:一项随机对照试验
  • 批准号:
    10668324
  • 财政年份:
    2022
  • 资助金额:
    $ 39.37万
  • 项目类别:
A Proof of Concept Trial of a Sirtuin-NAD+ Activator in Alzheimer's Disease
Sirtuin-NAD 激活剂治疗阿尔茨海默病的概念验证试验
  • 批准号:
    10311161
  • 财政年份:
    2021
  • 资助金额:
    $ 39.37万
  • 项目类别:
A Proof of Concept Trial of a Sirtuin-NAD+ Activator in Alzheimer's Disease
Sirtuin-NAD 激活剂治疗阿尔茨海默病的概念验证试验
  • 批准号:
    10457489
  • 财政年份:
    2021
  • 资助金额:
    $ 39.37万
  • 项目类别:
A Proof of Concept Trial of a Sirtuin-NAD+ Activator in Alzheimer's Disease
Sirtuin-NAD 激活剂治疗阿尔茨海默病的概念验证试验
  • 批准号:
    10634622
  • 财政年份:
    2021
  • 资助金额:
    $ 39.37万
  • 项目类别:
Improving Quality of Life of Prostate Cancer Survivors with Androgen Deficiency
改善雄激素缺乏的前列腺癌幸存者的生活质量
  • 批准号:
    10398005
  • 财政年份:
    2018
  • 资助金额:
    $ 39.37万
  • 项目类别:
Multimodality Intervention to Improve Function and Metabolism in Spinal Cord Injury
多模式干预改善脊髓损伤的功能和代谢
  • 批准号:
    9767249
  • 财政年份:
    2018
  • 资助金额:
    $ 39.37万
  • 项目类别:
Multimodality Intervention to Improve Function and Metabolism in Spinal Cord Injury
多模式干预改善脊髓损伤的功能和代谢
  • 批准号:
    10159744
  • 财政年份:
    2018
  • 资助金额:
    $ 39.37万
  • 项目类别:
Multimodality Intervention to Improve Function and Metabolism in Spinal Cord Injury
多模式干预改善脊髓损伤的功能和代谢
  • 批准号:
    10398790
  • 财政年份:
    2018
  • 资助金额:
    $ 39.37万
  • 项目类别:
Improving Quality of Life of Prostate Cancer Survivors with Androgen Deficiency
改善雄激素缺乏的前列腺癌幸存者的生活质量
  • 批准号:
    9918241
  • 财政年份:
    2018
  • 资助金额:
    $ 39.37万
  • 项目类别:

相似海外基金

Proton-secreting epithelial cells as key modulators of epididymal mucosal immunity - Administrative Supplement
质子分泌上皮细胞作为附睾粘膜免疫的关键调节剂 - 行政补充
  • 批准号:
    10833895
  • 财政年份:
    2023
  • 资助金额:
    $ 39.37万
  • 项目类别:
A Longitudinal Qualitative Study of Fentanyl-Stimulant Polysubstance Use Among People Experiencing Homelessness (Administrative supplement)
无家可归者使用芬太尼兴奋剂多物质的纵向定性研究(行政补充)
  • 批准号:
    10841820
  • 财政年份:
    2023
  • 资助金额:
    $ 39.37万
  • 项目类别:
StrokeNet Administrative Supplement for the Funding Extension
StrokeNet 资助延期行政补充文件
  • 批准号:
    10850135
  • 财政年份:
    2023
  • 资助金额:
    $ 39.37万
  • 项目类别:
2023 NINDS Landis Mentorship Award - Administrative Supplement to NS121106 Control of Axon Initial Segment in Epilepsy
2023 年 NINDS 兰迪斯指导奖 - NS121106 癫痫轴突初始段控制的行政补充
  • 批准号:
    10896844
  • 财政年份:
    2023
  • 资助金额:
    $ 39.37万
  • 项目类别:
Biomarkers of Disease in Alcoholic Hepatitis Administrative Supplement
酒精性肝炎行政补充剂中疾病的生物标志物
  • 批准号:
    10840220
  • 财政年份:
    2023
  • 资助金额:
    $ 39.37万
  • 项目类别:
Administrative Supplement: Life-Space and Activity Digital Markers for Detection of Cognitive Decline in Community-Dwelling Older Adults: The RAMS Study
行政补充:用于检测社区老年人认知衰退的生活空间和活动数字标记:RAMS 研究
  • 批准号:
    10844667
  • 财政年份:
    2023
  • 资助金额:
    $ 39.37万
  • 项目类别:
Administrative Supplement: Improving Inference of Genetic Architecture and Selection with African Genomes
行政补充:利用非洲基因组改进遗传结构的推断和选择
  • 批准号:
    10891050
  • 财政年份:
    2023
  • 资助金额:
    $ 39.37万
  • 项目类别:
Power-Up Study Administrative Supplement to Promote Diversity
促进多元化的 Power-Up 研究行政补充
  • 批准号:
    10711717
  • 财政年份:
    2023
  • 资助金额:
    $ 39.37万
  • 项目类别:
Administrative Supplement for Peer-Delivered and Technology-Assisted Integrated Illness Management and Recovery
同行交付和技术辅助的综合疾病管理和康复的行政补充
  • 批准号:
    10811292
  • 财政年份:
    2023
  • 资助金额:
    $ 39.37万
  • 项目类别:
Administrative Supplement: Genome Resources for Model Amphibians
行政补充:模型两栖动物基因组资源
  • 批准号:
    10806365
  • 财政年份:
    2023
  • 资助金额:
    $ 39.37万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了